Roche plans to close four manufacturing sites in Clarecastle, Ireland; Leganes, Spain; Segrate, Italy; and Florence, U.S. to address current underutilization as a result of its evolving portfolio. The company is looking into divestment opportunities for these facilities.   To support the manufacture of a new generation of specialized small molecule medicines—produced in lower volumes than traditional medicines—Roche is investing 300 million Swiss francs in a dedicated facility in Kaiseraugst, ...